DexCom (DXCM) Competitors

DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Do institutionals & insiders have more ownership in DXCM or HQY?

97.8% of DexCom shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 1.5% of HealthEquity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has better earnings & valuation, DXCM or HQY?

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.03B	7.80	$576.20M	$1.44	55.67
HealthEquity	$1.20B	6.70	$96.70M	$1.37	67.87

Does the media refer more to DXCM or HQY?

In the previous week, DexCom had 14 more articles in the media than HealthEquity. MarketBeat recorded 26 mentions for DexCom and 12 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.38 beat DexCom's score of 1.20 indicating that HealthEquity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	20 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, DXCM or HQY?

DexCom has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Do analysts rate DXCM or HQY?

DexCom currently has a consensus target price of $99.89, suggesting a potential upside of 24.60%. HealthEquity has a consensus target price of $118.55, suggesting a potential upside of 27.50%. Given HealthEquity's stronger consensus rating and higher probable upside, analysts clearly believe HealthEquity is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
HealthEquity	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is DXCM or HQY more profitable?

DexCom has a net margin of 13.29% compared to HealthEquity's net margin of 9.80%. DexCom's return on equity of 30.41% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	13.29%	30.41%	10.08%
HealthEquity	9.80%	11.01%	6.77%

Summary

DexCom beats HealthEquity on 11 of the 17 factors compared between the two stocks.